0H8E.L

Accelerate Diagnostics, Inc. (ADI) is a company specializing in in vitro diagnostics, providing essential tools for identifying severe infections across the United States, Europe, and the Middle East. Central to its product line is the Accelerate Pheno system, an advanced in vitro diagnostic platform. This system is designed to rapidly identify a wide range of pathogens – including both gram-positive and gram-negative organisms – responsible for serious or healthcare-acquired infections, and to determine their susceptibility to various antibiotics. Complementing this platform, ADI also supplies the Accelerate PhenoTest. This specialized test kit is utilized to quickly generate identification and antibiotic susceptibility data for patients suspected of developing bacteremia or fungemia – critical, life-threatening blood infections that carry a substantial risk of illness and mortality. Initially established in 1982 as Accelr8 Technology Corporation, the company officially rebranded to Accelerate Diagnostics, Inc. in December 2012. Its corporate headquarters are situated in Tucson, Arizona.